Research On Improvement Of Drug R&D Strategy Of Company A

Recently,within the rapid economic growth and the government's increasing focus on projects affecting people's well-being,China's pharmaceutical industry has been standardized while enjoying rapid growth.It is predicted that by 2020,following the United States,China will become the second largest pharmaceutical market in the world.However,within the expansion of the market scale,the serious problems of insufficient R&D investment and product homogeneity occur.Pharmaceutical industry is a recognized knowledge-intensive industry and also high-tech industry.The characteristics of this industry are continually adjusting and renewing product structure while innovating the technology.Nowadays,countries are emphasizing the protection of intellectual property.India,as one of the leaders for generic drug,has also been criticized by many countries.The current main stream of pharmaceutical R&D in China is generic drug,and the foundation of independent R&D capacity is weak,and most pharmaceutical enterprise lack systematic and effective R&D planning and strategy.How to effectively combine the company's core competitiveness with drug R&D model and market demand;How to seek funding support while optimizing the present product structure and maintain market share;How to promote technical cooperation,innovate R&D and explore new areas,are urgent problems to be solved.Based on the macro background of the pharmaceutical industry and the involved theories,this paper analyses the problems existing in drug R&D of Company A from the aspects of internal environment and company's conditions,and finds out the causes of these problems.Then,it puts forward feasible R&D strategies for specific R&D problems,improves the current R&D strategy of Company A,determines the content of the new R&D strategy and sets the corresponding implementation steps and safeguards.Finally,regarding the transfer of intellectual property rights as the main way,strengthening cooperation with other research institutions and enterprises,which is ensured by sustained financial support and comprehensive government protection,jointly promoting the R&D of new drugs,company A achieves the goal of breakthroughs in R&D model oriented by the product and function.The topic for this paper is to improve the company A's R&D strategy,more specifically,to innovate the conventional R&D strategy,and put forward the R&D strategy of "relay collaboration",which is decided after introducing the present conditions of China's pharmaceutical industry from the aspects of industry situation,relevant data,national policy and market trend,and explain the characteristics of China's pharmaceutical industry.Then,by the means of the theory of enterprise competitiveness,strategic management theory,and other theories,this paper clarifies the internal and external situation of company A,analyses its advantages and disadvantages.On the premise of actual situation,it puts forward the pharmaceutical R&D strategy of company A: in the initial stage,we need to adjust and optimize company A's product structure and redevelop present varieties,and then combine the concept of "me-too" and "me-better" to carry out similar drug innovations,which is the strong backing for the ultimate realization of the research and development of completely innovative varieties;For the drug research and development mode,the collaborative steps R&D mode should be adopted,to cooperate with laboratories,scientific research institutes and CRO companies of major hospitals and colleges.In the end,the fully carried out process of pharmaceutical R&D strategy and the supporting safeguards are worked out.Pharmaceutical R&D strategy is a significant part of the development strategy of pharmaceutical enterprises.I hope that this paper can help Company A improve the current pharmaceutical R&D mode,constantly enhance the competitiveness of enterprise,and also can be a example for other domestic pharmaceutical enterprises to formulate strategies.